SOLICITATION NOTICE
Q -- miRNA Replication of SABRe CVD miRNA analysis discovery work - Package #1
- Notice Date
- 9/9/2013
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HL)-2013-276-DDC
- Archive Date
- 9/28/2013
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Justification and Approval (J&A) INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the of the Population Sciences Branch/Framingham Heart Study (NHLBI), intends to negotiate and award a purchase order on a noncompetitive sole source basis without providing for full and open competition to University Massachusetts Medical School, 381 Plantation Street, Biotech V, Suite 200, Worchester, MA 01605-431972 East Concord St, B-606, Boston, MA 02118 to procure reagents and provide assay services for the screening and measurement of miRNA in 1000 samples used for a replication study. Procurement: Contractor Requirements: A. Contractor will provide miRNA services. The contractor will process 1000 ARIC Study samples at contractor location using standard genotyping methods. B. Contractor will include 192 miRNA and 2000 samples C. The Contractor will provide high quality assay results with: • Blind duplicates with concordant results >95% D. Quality control measures will be applied by the Contractor and assay results will be accomplished by quality control information reflecting QC E. Contractor will specify any special packaging, marking, or shipping instructions for sample shipment. F. Contractor must have letter of authorization from University of University Massachusetts Medical School, to perform these services Background: Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute; NHLBI) -- embarked on an ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. Framingham SABRe CVD initiative will assess biomarkers in approximately 700 Framingham Heart Study Offspring and Third Generation cohort participants. Thousands of biomarkers will be assessed using the following platforms: a) immunoassays, b) discovery and targeted proteomics, c) discovery and targeted Metabolomics/lipomics, and WBC derived RNA expression. SABRe CVD represents an opportunity to conduct complex systems biology science on a population level. In this collaborative effort in biomarker discovery, the UMASs miRNA core has undertaken the biomarker discovery project for analysis of ~7000 samples on TaqMan arrays to identify differentially expressed miRNA. Purpose and Objective: Purchase of reagents and provide assay services for the screening and measurement of miRNA in 1000 samples used for a replication study. Government intends to replicate the top 192 miRNA with altered expression in heart, lung, and blood disorders, and in parallel study alternative splicing events during the disease process. The results will be compared and analyzed with the discovery data collected in over 7000 Framingham Heart Study samples. Completion of this replication study is critical to the ability to publish these results that should have an impact on public health and the future of biomarker prediction of CVD and NHLBI related conditions. Period of Performance: Period of performance is schedule from 9/25/2013-9/24/2014 Government Responsibilities: Will provide the list of 192 miRNA targets Will provide >3.0ug of clean RNA from 1000 samples Reporting Requirements and Deliverables: A. miRNA results will be returned by Contractor to the Framingham Heart Study in a standard format in a nonproprietary database in which each gene is identified by a standard name. B. Return of miRNA results by the Contractor will be accompanied by summary quality control measures for each gene. C. miRNA results will be returned to the Study within a mutually agreed upon timeline tied to the receipt of the gene list and appropriate RNA samples identified. Justification: Refer to attached Justification and Approval Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION Industry Classification (NAICS) Code is 541380 and the Small Business Size Standard is $14.0M. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-69 (August 1st 2013). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by September 13, 2013, 9:00 am eastern standard time and must reference synopsis number HHS-NIH- NHLBI-CSB-(HL)-2013-276-DDC, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6142, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HL)-2013-276-DDC/listing.html)
- Record
- SN03180838-W 20130911/130910000133-30bd7d0e2ab5ee841bfd37c2f3a97aff (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |